March 11, 2013. Among experts in women’s health and experts in breast cancer, there is considerable concern about Assembly Bill 147 and similar legislation in other states. While we agree that women with dense breasts should discuss the implications of that health condition with their physician, we are concerned that women who receive required form letters are more frightened than informed.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony to the FDA Joint Advisory Committee of the FDA on Calcitonin
March 5, 2013. Dr. Jennings testifies to the FDA that the risks of using calcitonin to prevent bone fractures in post-menopausal are greater than the potential benefits.
Read More »NCHR Testimony on Gabapentin
March 4, 2013. Dr. Jennings testifies to the FDA that there is not sufficient evidence to support gabapentin as a safe and effective treatment for hot flashes.
Read More »NCHR Testimony on Paroxetine (Brisdelle)
March 4, 2013. Dr. Mary Carol Jennings testifies to the FDA on the risks of using Paroxetine (Brisdelle) to treat hot flashes.
Read More »NCHR Testimony on Creating an Alternative Approval Pathway for Drugs to Address Unmet Medical Need
February 4, 2013. Dr. Yttri testifies at an FDA public hearing that a new, expedited pathway for drug approval is poorly-defined and would promote unproven drugs to high-risk patients.
Read More »